Knight Therapeutics (TSE:GUD) Rating Increased to Strong-Buy at Stifel Canada

Stifel Canada upgraded shares of Knight Therapeutics (TSE:GUD) from a hold rating to a strong-buy rating in a research note released on Monday, Zacks.com reports. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2024 earnings at $0.06 EPS and FY2024 earnings at $0.06 EPS.

Separately, Stifel Nicolaus upgraded Knight Therapeutics from a hold rating to a buy rating and increased their target price for the company from C$5.75 to C$6.75 in a research report on Tuesday.

Knight Therapeutics Price Performance

Shares of Knight Therapeutics stock opened at C$5.69 on Monday. The firm has a market cap of C$576.85 million, a PE ratio of -35.56, a P/E/G ratio of -1,013.50 and a beta of 0.46. The business has a 50-day moving average price of C$5.66 and a 200 day moving average price of C$5.64. The company has a quick ratio of 1.79, a current ratio of 3.34 and a debt-to-equity ratio of 9.20. Knight Therapeutics has a twelve month low of C$4.35 and a twelve month high of C$6.22.

Insider Buying and Selling

In other Knight Therapeutics news, Senior Officer Amal Khouri sold 20,000 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of C$5.80, for a total transaction of C$116,022.00. In other Knight Therapeutics news, Senior Officer Amal Khouri sold 20,000 shares of Knight Therapeutics stock in a transaction on Monday, June 10th. The shares were sold at an average price of C$5.80, for a total transaction of C$116,022.00. Also, Director Robert Nathaniel Lande sold 15,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of C$5.91, for a total transaction of C$88,600.50. In the last three months, insiders have sold 80,000 shares of company stock worth $466,283. Insiders own 46.36% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.